Newcells Biotech

Alchemab is harnessing the naturally protective power of patient antibodies to keep people free of hard-to-treat disease in a unique and transformative approach to drug discovery and development. Alchemab takes an unbiased and function-first approach using three complementary processes and cutting-edge technologies to identify naturally protective antibodies. Alchemab’s engine is enabled through collaborations with patient representative groups and biobanks around the world with whom we partner to further our understanding of disease.

Biodexa Pharmaceuticals is an international specialty pharmaceutical company focused on oncology and other therapeutic areas with a commercial platform and four marketed products in the US. Midatech's strategy is to develop products in-house in oncology and with partners in other indications, and to accelerate growth organically and through strategic acquisitions.

Concert Bio helps businesses create optimal microbial communities.

RQ Bio is a biotechnology company that develops long-acting monoclonal antibodies against seasonal influenza with the goal of providing immediate, powerful, and long-lasting protection against severe viral disease in immunocompromised and high-risk subjects. The company's mission is to deliver "instant immunity" through passive immunization, helping protect vulnerable populations such as the elderly, newborns, and immunocompromised patients from severe infectious diseases. The company specializes in the discovery and development of broad-spectrum antiviral antibodies that are engineered to remain effective even as viruses evolve. Its scientific approach combines virology, antibody engineering, computational biology, and immune-directed discovery techniques to identify potent antibodies that target conserved regions of viral proteins, reducing the risk of resistance caused by viral mutations. RQ Bio's lead programs focus on infectious diseases such as influenza, COVID-19, respiratory syncytial virus (RSV), and cytomegalovirus (CMV). The company is currently developing long-acting monoclonal antibodies designed to provide once-yearly protection against seasonal influenza, particularly for individuals at high risk of severe disease.

N4 Pharma is a drug reformulation company focused on developing and out licensing new versions of existing and novel high value drugs with an unmet commercial or medical need . N4’s commercial strategy is to advance a pipeline of products through clinical proof of concept and then partner to take the products through the relevant regulatory pathway studies to regulatory approval.

Laverock Therapeutics is working on developing a system for suppressing genes, which can be used to create customizable cell therapies that are compatible with different individuals.

Oak hill bio is a clinical-stage rare disease therapeutics company developing life-changing medicines.

IMU is a discovery engine mapping the immune system to advance precision medicine.

Mykor is a climate tech start-up. It decarbonizes the construction industry by manufacturing carbon-negative materials.

Neurovalens provides cutting-edge solutions in the realms of neuroscience, bioscience, and neurophysiology. With backing from Invest NI through the EU's Investment for Growth and Jobs Programme, Neurovalens' project will focus on research and development over the coming year to enhance the company's competitiveness.

Voxmind's biometric confirmation and authentication platform that provides voice based biometrics that helps with security and reduces fraud risk.

Five is a biometric payment services company that offers thumb recognition technology for safe transactions.